FIDSON • NSE

Fidson Healthcare Plc

14.35

NGN

-1.55 -9.75%

Open Price

15.90

Previous Close

15.90

Today’s Range

14.35 - 15.90

Number of Deals

Volume Traded

126,311.00

Value Traded

1,812,624.00

52 Weeks High

19.20

52 Weeks Low

8.50

Market Cap

29,939,269,587.50

YTD Price Performance

59.44 %

Fidson Healthcare Plc Declares N3.57bn PAT in Q3 2023 Results,(SP:N15)

November 1st, 2023 at 4:46 PM

Fidson Healthcare Plc to Hold the 108th Board Meeting on October 26, 2023

October 19th, 2023 at 4:10 AM

Fidson Healthcare Plc Declares N2.77bn PAT in Q2 2023 Results,(SP:N15.5k)

August 9th, 2023 at 5:28 PM

Q2 Unaudited Financial Statements for the Period ended 30th June 2023 - FIDSON HEALTHCARE PLC

August 7th, 2023 at 8:54 PM

GCR Affirms Fidson Healthcare Plc’s Issuer ratings of A(NG)/A1(NG), Underpinned by its Favourable Competitive Position and Strong Earnings, Outlook Stable

June 27th, 2023 at 9:02 PM

Fidson Healthcare Board Approves 2022 AFS; Recommends Payment of 55k Dividend per Share

March 24th, 2023 at 3:36 PM

Fidson Healthcare Plc Declares N4.14bn PAT in Q4 2022 Unaudited Results, (SP: N9.89K)

February 2nd, 2023 at 1:17 PM

Fidson Healthcare Plc Declares N3.44bn PAT in Q3 2022 Unaudited Results, (SP: N8.85K)

November 28th, 2022 at 2:29 PM

Fidson Healthcare Plc Notifies of Board Meeting; Declares Closed Period

November 1st, 2022 at 12:02 PM

Fidson Healthcare Plc Notifies on Resolutions Passed at 23rd AGM

August 24th, 2022 at 2:30 PM

Key Stats

Shares Outstanding

2,086,360,250.00

Net Assets

0.00

Book Value Per Share

0.00

Sector P/E

55.44

EPS

0.68

P/E

21.10

ROE

0.00

Dividend Yield

1.05

About Company

Manufacturing and Distributin of Pharmaceutical Products

Sector

Healthcare

Sub Sector

Pharmaceutical

Management

Olugbenga Olayeye

Fidelis Ayebae

Biola Adebayo

Address

268, Ikorodu Road, Obanikoro P. O. Box 7210, Shomolu, Lagos, Nigeria

Phone No

"+234 (0) 8077008888 +234 (1) 342 9102"

Email Address

[email protected]

Website

https://www.fidson.com/

Board of Directors

Fidelis Ayebae

Biola Adebayo

Emmanuel E. Imoagene

Olugbenga Olayeye

Olufunmilola Ayebae

Segun Adebanji

Chief (Mrs.) A. P. Sadauki, OON

Social Media Accounts

Subsidiary

Company Secretary

J. Abayomi Adebanjo

End of Accounting Year

31 Dec

Listing Date

06/04/2008

Company Registrar

Regulatory Status

Free Float

0.00

Auditor

Touche

Shareholding Pattern

Analyst Reports

Q3 Unaudited Financial Statement for the Period Ended September 30, 2023 - Fidson Healthcare Plc

Q3 Unaudited Financial Statement for the Period Ended September 30, 2023

November 3rd, 2023 at 10:33 AM

Q4 2022 Unaudited Financial Statements for the Period ended 31st December 2022 – Fidson Healthcare Plc

Fidson Healthcare Plc releases its Financial Result for the Period ended 31st December 2022

February 9th, 2023 at 5:36 PM

2021 Audited Financial Statements for the Period ended 31st December 2021 – Fidson Healthcare Plc

Fidson Healthcare Plc released its 2021 Audited results for the period ended December 31st, 2021. Revenue grew by 16.7% from N18.28bn to N30.86bn, Profit before tax stood at N4.72bn, Profit after tax stood at N3.72bn, Share Price Currently Stands at N8.00k

April 25th, 2022 at 9:55 AM

Income

Q3, 2023 and Q3, 2022 Financial Performance Comparison

Profit & loss information

Description	Q 3, 2023 N'm	Q 3, 2022 N'm	% Change
Gross Earnings	0.00	0.00	+ 0.00%
Profit Before Tax	5,290.00	5,096.00	+ 3.81%
Income Tax Expense	-1,719.00	-1,656.00	+ 3.80%
Taxation	-1,719.00	0.00	+ 0.00%
Profit After Tax	3,571.00	0.00	+ 0.00%
Fixed Assets	19,438.00	17,206.00	+ 12.97%
Total Assets	50,880.00	42,415.00	+ 19.96%
Customers Deposits	0.00	0.00	+ 0.00%
Loans and Advances	0.00	0.00	+ 0.00%
Total Liabilities	31,651.00	26,267.00	+ 20.50%
Borrowings	3,837.00	0.00	+ 0.00%
Cash Flow From Operating Activities	0.00	0.00	+ 0.00%

Income

Description	Q 3, 2023 N'm	Q 2, 2023 N'm	Q 1, 2023 N'm	Q 3, 2022 N'm	Q 1, 2022 N'm
Gross Earnings	0.00	0.00	0.00	0.00	0.00
Gross Premium Written	0.00	0.00	0.00	0.00	0.00
Revenue	14,794.00	25,580.00	11,405.00	31,428.00	10,244.00
Turnover	0.00	0.00	0.00	0.00	0.00
Interest And Similar Income	0.00	0.00	0.00	0.00	0.00
Gross Premium Income	0.00	0.00	0.00	0.00	0.00
Cost Of Sales	24,813.00	-14,522.00	-6,515.00	-16,938.00	-5,783.00

Description	Q 3, 2023 N'm	Q 2, 2023 N'm	Q 1, 2023 N'm	Q 3, 2022 N'm	Q 1, 2022 N'm
Property Plant And Equipment	19,438.00	19,426.00	19,269.00	17,206.00	16,355.00
Fair Value Movements On Equity Instruments	0.00	0.00	0.00	0.00	0.00
Value Through Profit Or Loss	0.00	0.00	0.00	0.00	0.00
Intangible Assets	45.00	46.00	62.00	29.00	20.00
Fair Value Movements On Debt Securities	0.00	0.00	0.00	0.00	0.00
Management Expenses	0.00	0.00	0.00	0.00	0.00
Other Non Current Assets	0.00	0.00	0.00	172.00	0.00

Description	Q 3, 2023 N'm	Q 2, 2023 N'm	Q 1, 2023 N'm
Cash Flow From Operating Activities	0.00	0.00	0.00
Total Premium Received	0.00	0.00	0.00
Receipt From Reinsurance Recovery	0.00	0.00	0.00
Reinsurance Premium Paid	0.00	0.00	0.00
Profit For The Period	5,290.00	4,106.00	2,017.00
Commission Received	0.00	0.00	0.00
Claims Recoveries	0.00	0.00	0.00

Remark	Date
Notice of the Board of Directors’ Meeting in consideration and approval of the audited financial statements for the year ended 31st December 2023.	3/28/2024
Notice of board meting for the consideration and approval of the unaudited financial statements for the third quarter ended 30th September 2023	10/26/2023

Dividend	Dividend Type	Announement Date	Payment Date	Date
0.15	Final	6/15/2020	7/24/2020	7/7/2020
0.15	Final	4/1/2019		4/18/2019
0.05		4/1/2016		4/1/2016
0.15	Final	3/26/2015	10/16/2015	10/5/2015
0.10	Final	5/2/2014	7/18/2014	7/7/2014
0.12	Final	5/2/2013		5/2/2013
0.10	Final	4/20/2012		4/20/2012
0.10	Final	1/27/2011	3/11/2011	2/3/2011
0.22	Final			1/19/2010
0.20				12/19/2008

Bonus	Bonus Type	Announement Date	Payment Date	Date

New Face Value	Old Face Value	Exsplit Date	Announement Date

Book Closure	Address	Announement Date	Date
7/14/2023	Banquet Hall, Sheraton Hotels and Towers, 30 Mobolaji Bank-Anthony Way, Ikeja Lagos at 10.00 a.m	8/1/2023	9/11/2023
	Conference Centre 2nd Floor, Fidson Towers, 268 Ikorodu Road, Obanikoro, Lagos	7/8/2022	7/28/2022
7/8/2021	Conference Centre 2nd Floor, Fidson Towers, 268 Ikorodu Road, Obanikoro, Lagos at 12noon	6/10/2021	7/28/2021
7/7/2020	Conference Centre 2nd Floor, Fidson Towers, 268 Ikorodu Road, Obanikoro, Lagos at 11am	6/15/2020	7/23/2020
10/5/2015	Sheraton Hotels & Towers. Mobolaji Bank Anthony way, Ikeja, Lagos.	9/11/2015	10/14/2015
7/7/2014	Mbanefo Hall, Golden Tulip Hotel, Amuwo Odofin, Fethac Town, Lagos	5/2/2014	7/17/2014
2/3/2011	Sheraton Hotel and Towers Ikeja, Lagos thate	1/27/2011	2/23/2011
1/19/2010			2/25/2010

Technical Rating

Very Bullish
See details
View historical rating

Moving averages

Billish
Moving averages

Billish
Moving averages crossovers

Natural

Pivot levels

Trend	R1	R2	R3	PP	S1	S2	S3
Classic	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72
Classic	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72
Classic	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72

Note: This is just a sample text, change appropriately.

Moving average

Days
- HTML
- CSS
- JavaScript
5

1,344.77
10

1,344.77
20

1,344.77
50

1,344.77
100

1,344.77
200

1,344.77

Name of chart*

Technical Rating

Very Bullish
See details
View historical rating

Moving averages

Billish
Moving averages

Billish
Moving averages crossovers

Natural

Pivot levels

Trend	R1	R2	R3	PP	S1	S2	S3
Classic	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72
Classic	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72
Classic	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72

Note: This is just a sample text, change appropriately.

Moving average

Days
- HTML
- CSS
- JavaScript
5

1,344.77
10

1,344.77
20

1,344.77
50

1,344.77
100

1,344.77
200

1,344.77

Name of chart*

Technical Rating

Very Bullish
See details
View historical rating

Moving averages

Billish
Moving averages

Billish
Moving averages crossovers

Natural

Pivot levels

Trend	R1	R2	R3	PP	S1	S2	S3
Classic	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72
Classic	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72
Classic	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72	1,565.72

Note: This is just a sample text, change appropriately.

Moving average

Days
- HTML
- CSS
- JavaScript
5

1,344.77
10

1,344.77
20

1,344.77
50

1,344.77
100

1,344.77
200

1,344.77

Name of chart*

Q 1, 2023

Price to book

0.00
Price to sales

2.63
Dividend yield

1.05
Net Debt

3,070.00
Price Earning Including Extra Items

22.00
Price Earning Normalized

25.47
Price To Free Cash Flow

102.53
Price To Tangible Book

0.68

Q 2, 2023

Price to book

0.00
Price to sales

1.17
Dividend yield

1.05
Net Debt

580.00
Price Earning Including Extra Items

21.22
Price Earning Normalized

24.56
Price To Free Cash Flow

8.43
Price To Tangible Book

0.63

Q 3, 2023

Price to book

0.00
Price to sales

2.02
Dividend yield

1.05
Net Debt

-19.00
Price Earning Including Extra Items

8.38
Price Earning Normalized

9.71
Price To Free Cash Flow

6.28
Price To Tangible Book

0.59

Q 1, 2023

Gross Revenue Margin

157.12
Gross Profit Margin

157.12
Net Interest Margin

0.00
Net Profit Margin

11.93
Operating Cash Flow/Revenue

2.56
Operating Profit Margin (%)

0.00
Pretax Margin

17.69

Q 2, 2023

Gross Revenue Margin

156.77
Gross Profit Margin

156.77
Net Interest Margin

0.00
Net Profit Margin

5.52
Operating Cash Flow/Revenue

13.88
Operating Profit Margin (%)

0.00
Pretax Margin

16.05

Q 3, 2023

Gross Revenue Margin

-67.72
Gross Profit Margin

-67.72
Net Interest Margin

0.00
Net Profit Margin

24.14
Operating Cash Flow/Revenue

32.25
Operating Profit Margin (%)

0.00
Pretax Margin

35.76

Q 1, 2023

Book Value Growth Rate

0.00
Capital Expenditure Growth Rate

0.00
Deposit Growth

0.00
Dividend Growth

0.00
EBITDA

0.00
EPS Growth Rate

0.00
Fixed Asset Growth

11.99
Impairment Growth

0.00
Loan Growth

-33.63
Net Assets growth

0.00
Net Profit Margin Growth Rate

0.00
Operating Cash Flow

292.00
Revenue Growth

-63.71
Shareholder Fund Growth

0.00
Total Assets Growth

3.65
Total Liabilities Growth

-2.22

Q 2, 2023

Book Value Growth Rate

0.00
Capital Expenditure Growth Rate

0.00
Deposit Growth

0.00
Dividend Growth

0.00
EBITDA

0.00
EPS Growth Rate

3.67
Fixed Asset Growth

12.90
Impairment Growth

0.00
Loan Growth

0.00
Net Assets growth

0.00
Net Profit Margin Growth Rate

-100.00
Operating Cash Flow

3,551.00
Revenue Growth

124.29
Shareholder Fund Growth

0.00
Total Assets Growth

8.09
Total Liabilities Growth

8.34

Q 3, 2023

Book Value Growth Rate

0.00
Capital Expenditure Growth Rate

0.00
Deposit Growth

0.00
Dividend Growth

0.00
EBITDA

0.00
EPS Growth Rate

153.08
Fixed Asset Growth

12.97
Impairment Growth

0.00
Loan Growth

34.84
Net Assets growth

0.00
Net Profit Margin Growth Rate

-100.00
Operating Cash Flow

4,771.00
Revenue Growth

-42.17
Shareholder Fund Growth

0.00
Total Assets Growth

7.07
Total Liabilities Growth

13.74

Q 1, 2023

Book Value per share

0.00
Cash Per Share

1.00
Dividend Per Share

0.15
EPS Basic Excl. Extra Items

0.65
EPS Excl. Extra Items

0.65
EPS Incl. Extra Items

0.00
EPS Normalized

0.65
Revenue Per Share

5.47

Q 2, 2023

Book Value per share

0.00
Cash Per Share

1.40
Dividend Per Share

0.15
EPS Basic Excl. Extra Items

0.68
EPS Excl. Extra Items

0.68
EPS Incl. Extra Items

0.00
EPS Normalized

0.68
Revenue Per Share

12.26

Q 3, 2023

Book Value per share

0.00
Cash Per Share

1.85
Dividend Per Share

0.15
EPS Basic Excl. Extra Items

1.71
EPS Excl. Extra Items

1.71
EPS Incl. Extra Items

0.00
EPS Normalized

1.71
Revenue Per Share

7.09

Q 1, 2023

Acid Test Ratio

0.52
Claims Ratio

0.00
Cost to Income Ratio

0.00
Current Ratio

1.37
Investment Ratio

0.00
Leverage Ratio

0.00
Liquidity Ratio

0.05
Long Term Debt/Equity

0.00
Net Interest Coverage

0.00
Payout Ratio

0.23
Quick Ratio

0.52
Reserve Ratio

0.00
Total Debt/Total Equity

0.00

Q 2, 2023

Acid Test Ratio

0.71
Claims Ratio

0.00
Cost to Income Ratio

0.00
Current Ratio

1.39
Investment Ratio

0.00
Leverage Ratio

0.00
Liquidity Ratio

0.06
Long Term Debt/Equity

0.00
Net Interest Coverage

0.00
Payout Ratio

0.22
Quick Ratio

0.71
Reserve Ratio

0.00
Total Debt/Total Equity

0.00

Q 3, 2023

Acid Test Ratio

0.82
Claims Ratio

0.00
Cost to Income Ratio

0.00
Current Ratio

1.46
Investment Ratio

0.00
Leverage Ratio

0.00
Liquidity Ratio

0.08
Long Term Debt/Equity

0.00
Net Interest Coverage

0.00
Payout Ratio

0.09
Quick Ratio

0.82
Reserve Ratio

0.00
Total Debt/Total Equity

0.00

Q 1, 2023

Annual % Change in Highest Directors Pay

0.00
Annual % Change in PBT

-60.42
Annual % Change in Share Price

-18.00
Annual % Change in Staff Cost

0.00
Asset Turnover

0.26
Dividend Payout Ratio

0.23
Highest Directors’ Pay to PBT Ratio

0.00
Highest Directors’ Pay to Revenue Ratio

0.00
Highest Directors’ Pay vs PBT

0.00
Highest Directors’ Pay vs Revenue

0.00
Highest Directors’ Pay vs Staff Cost

0.00
Inventory Turnover

-0.44
Net Income/Employee

0.00
Receivables Turnover

0.00
Return on Assets

0.05
Return on Average Assets

0.03
Return on Average Equity

0.00
Return on Equity

0.00
Return on Investment

-0.02
Revenue/Employee

0.00
Staff Cost vs PBT

0.00
Staff Cost vs Revenue

0.00

Q 2, 2023

Annual % Change in Highest Directors Pay

0.00
Annual % Change in PBT

103.57
Annual % Change in Share Price

-18.00
Annual % Change in Staff Cost

0.00
Asset Turnover

0.54
Dividend Payout Ratio

0.22
Highest Directors’ Pay to PBT Ratio

0.00
Highest Directors’ Pay to Revenue Ratio

0.00
Highest Directors’ Pay vs PBT

0.00
Highest Directors’ Pay vs Revenue

0.00
Highest Directors’ Pay vs Staff Cost

0.00
Inventory Turnover

-1.07
Net Income/Employee

0.00
Receivables Turnover

0.00
Return on Assets

0.09
Return on Average Assets

0.03
Return on Average Equity

0.00
Return on Equity

0.00
Return on Investment

0.02
Revenue/Employee

0.00
Staff Cost vs PBT

0.00
Staff Cost vs Revenue

0.00

Q 3, 2023

Annual % Change in Highest Directors Pay

0.00
Annual % Change in PBT

28.84
Annual % Change in Share Price

-18.00
Annual % Change in Staff Cost

0.00
Asset Turnover

0.29
Dividend Payout Ratio

0.09
Highest Directors’ Pay to PBT Ratio

0.00
Highest Directors’ Pay to Revenue Ratio

0.00
Highest Directors’ Pay vs PBT

0.00
Highest Directors’ Pay vs Revenue

0.00
Highest Directors’ Pay vs Staff Cost

0.00
Inventory Turnover

1.84
Net Income/Employee

0.00
Receivables Turnover

0.00
Return on Assets

0.10
Return on Average Assets

0.07
Return on Average Equity

0.00
Return on Equity

0.00
Return on Investment

0.04
Revenue/Employee

0.00
Staff Cost vs PBT

0.00
Staff Cost vs Revenue

0.00

Price performance

1 week

-9.75%

1 month

-2.38%

3 months

-19.15%

6 months

-1.03%

9 months

-4.97%

1 years

59.44%

Volume analysis

1 week

466.42%

1 month

-83.09%

3 months

-91.66%

6 months

-85.67%

9 months

-88.07%

1 years

-37.57%

RELATED MEDIA

SIMILAR STOCKS

MAYBAKER Pharmaceutical

6.00 NGN 0%

MECURE Pharmaceutical

9.72 NGN 0%

NEIMETH Pharmaceutical

1.98 NGN +10.0% greenwhite-indicator

Proshare is a professional practice focused on delivering research and information services to bridge the gap between investors and markets; by delivery on credible, reliable, and timely engagements through the following areas — Impact Research, Market Intelligence, Strategic Advisory, Stakeholder Relations & Digital Media.